Jasper Therapeutics closed at $0.47 on Nov 5, down 8.20%, 77.1% below its 52-week closing high. Volume of 536.2K shares was 1.25× its 20-day average (above normal).
Split-adjusted performance: -17.6% over one month, -48.3% over six months, -74.1% over one year.
Short interest was 6.5M shares at the Oct 15 settlement, up 4.1% from the prior report (22.6% of float, 18.5 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −24.8%, revenue growth +8.5%, net margin −226.4%, P/E 21.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| JSPRJasper Therapeutics | $0.4692 | −8.20% | −48.3% | — | — | — | $15.6M | |
| ABOSAcumen Pharmaceuticals | $0.2138 | −1.16% | −91.3% | — | — | — | $15.5M | Compare |
| PLURPluri | $1.19 | −3.26% | −64.4% | −15.8% | −1755.2% | — | $16.1M | Compare |
| ATYRaTyr Pharma | $6.03 | −2.43% | −83.6% | — | — | — | $15.1M | Compare |
| ESLAEstrella Immunopharma | $0.4101 | −7.53% | −67.7% | — | — | — | $17.8M | Compare |
| DYAIDyadic International | $0.3401 | −7.25% | −54.3% | −0.6% | −221.0% | — | $13.6M | Compare |
| BCDABioCardia | $0.8900 | −2.53% | −18.3% | — | — | — | $13.5M | Compare |
| BKHABlack Hawk Acquisition | $4.50 | −19.21% | — | — | — | — | $18.7M | Compare |
| BSEMBioStem Technologies | $1.04 | −9.57% | — | — | — | — | $19.4M | Compare |
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
